Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immune Medicine operation and strengthened its balance sheet through a $340 million convertible note offering. Total revenue rose 30% year [...]
Adaptive Biotechnologies Q2 Earnings Call Highlights
